Core Insights - DiamiR Biosciences Corp. and Aptorum Group Limited are set to present at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, showcasing innovative blood-based diagnostic tests for brain health and neurodegeneration [1][4] Presentation Details - The presentations will occur on December 3, 2025, at the Hilton San Diego Bayfront, focusing on microRNA classifiers and their role in classifying cognitive impairment stages [2] - Poster 225 will discuss developing microRNA classifiers enriched in brain and inflammation in plasma samples, in collaboration with New York University [2] - Poster 240 will characterize stages of neurodegeneration using circulating brain-enriched and inflammation-associated microRNAs, in collaboration with the University of Pennsylvania [3] Merger Information - Aptorum Group and DiamiR have entered into a definitive agreement for an all-stock merger, with DiamiR becoming a wholly-owned subsidiary of Aptorum upon completion, expected in Q1 2026 [5] - The merger is subject to stockholder approval and customary closing conditions [5] Company Profiles - Aptorum Group is a clinical stage biopharmaceutical company focused on developing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [6] - DiamiR Biosciences specializes in developing minimally invasive tests for early detection and monitoring of brain health conditions, supported by over 50 issued patents [8]